Targeted Drug Delivery Systems

About Sanovas

Sanovas is a private, pre-revenue medical technology holding company founded in 2008, specializing in micro-invasive devices and targeted drug delivery for pulmonary and other conditions. The company operates by developing and spinning out specific technology platforms into separate ventures. Key challenges include its pre-commercial status, ongoing legal matters referenced on its website, and the regulatory pathway required for its investigational devices. Its strategy hinges on creating novel, minimally invasive platforms to address unmet needs in interventional pulmonology and beyond.

About Surflay Nanotec

Surflay Nanotec operates as a specialized technology provider and contract research organization at the intersection of nanotechnology, materials science, and biotechnology. Its core expertise lies in creating monodisperse fluorescent particles, microscaled sensors, and surface modification techniques, which are leveraged to develop solutions for partners in drug delivery, diagnostic assays, and industrial applications. The company appears to follow a B2B and collaborative R&D business model, offering both proprietary products like its WhisperSense protein interaction analyzer and custom development services. While not a traditional therapeutic developer, its enabling technologies support critical processes in biologics manufacturing, diagnostics, and controlled release systems.

Therapeutic Areas